Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07424222

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:28:21.908922+00:00

Published At

2026-02-23T00:00:00+00:00

Record Updated At

2026-02-23

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2026-02-23"

protocolSection.identificationModule.nctId

"NCT07424222"

protocolSection.identificationModule.officialTitle

"Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)"

protocolSection.statusModule.overallStatus

"NOT_YET_RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.